Monday, March 01, 2021

Avivagen Inc. (VIVXF)(VIV:CA)
Initiation Coverage of Avivagen: Well positioned Early Stage Ag-biotech Company

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal's own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating Coverage. We are initiating research coverage on Avivagen, Inc. Avivagen is an early-stage revenue company focused on developing and commercializing products for livestock, companion animals, and humans. We believe the Company is at an inflection point with significant sales increases just around the corner and presents a favorable risk/reward proposition.

Novel Therapeutic.  Avivagen's novel, proprietary technology, OxC-beta, helps support optimal immune function and helps animals achieve their full growth and productivity potential. The natural compound's benefits have been illustrated in over 40 research studies and trials. Avivagen has broad patent protection on OxC-beta ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.